Serum Sclerostin Levels in Healthy Men over 50 years of Age

Overview

Journal J Bone Miner Metab

Specialty Endocrinology

Date 2013 Mar 26

PMID 23525828

Citations 13

Authors

Harjit Pal Bhattoa

John Wamwaki

Edit Kalina

Roza Foldesi

Adam Balogh

Peter Antal-Szalmas

Affiliations

Soon will be listed here.

Abstract

The aim of this study is to evaluate the relationship of serum sclerostin levels with age, cystatin C, bone mineral density (BMD) and biochemical markers of bone turnover in healthy Hungarian men >50 years of age. We determined serum levels of sclerostin and examined its relationship to age, cystatin C, osteocalcin, C-terminal telopeptides of type-I collagen, procollagen type 1 amino-terminal propeptide, 25-hydroxyvitamin D, parathyroid hormone, and L1-L4 (LS) and femur neck (FN) BMD data available from 194 randomly selected ambulatory men belonging to the HunMen cohort. In the study population as a whole [n = 194; age (median, range) 59 (51-81) years], statistically significant correlation was found between sclerostin and age (r = 0.211; p = 0.003), cystatin C (r = 0.246; p = 0.001), FN BMD (r = 0.147; p = 0.041) and LS BMD (r = 0.169; p = 0.019). Compared to middle-aged men (age ≤59 years, n = 98), elderly men (age >59 years, n = 96) had significantly higher serum sclerostin levels (67.8 ± 15.9 vs 63.5 ± 14 pmol/L; p = 0.047). Among men with normal (T score >-1.0) FN BMD, the elderly had significantly higher serum sclerostin levels compared to the middle-aged men (70.4 ± 17 vs 63.9 ± 11.5 pmol/L; p = 0.019). Furthermore, among the elderly men cystatin C was the only significant predictor of serum sclerostin levels (standardized regression coefficient (β) = 0.487; p < 0.001). In the studied healthy elderly cohort, this study reports a significant increase in sclerostin levels with increasing age and deteriorating kidney function as determined by plasma cystatin C levels.

Citing Articles

Musculoskeletal Biomarkers Response to Exercise in Older Adults.

Abreu E, Vance A, Cheng A, Brotto M Front Aging. 2022; 3:867137.

PMID: 35821851 PMC: 9261344. DOI: 10.3389/fragi.2022.867137.

Positive and Negative Regulators of Sclerostin Expression.

Iwamoto R, Koide M, Udagawa N, Kobayashi Y Int J Mol Sci. 2022; 23(9).

PMID: 35563281 PMC: 9102037. DOI: 10.3390/ijms23094895.

Skeletal Aging and Osteoporosis: Mechanisms and Therapeutics.

Chandra A, Rajawat J Int J Mol Sci. 2021; 22(7).

PMID: 33805567 PMC: 8037620. DOI: 10.3390/ijms22073553.

Circulating bioactive sclerostin levels in an Austrian population-based cohort.

Kerschan-Schindl K, Foger-Samwald U, Gleiss A, Kudlacek S, Wallwitz J, Pietschmann P Wien Klin Wochenschr. 2021; 134(1-2):39-44.

PMID: 33544208 PMC: 8813720. DOI: 10.1007/s00508-021-01815-0.

Bone Metabolism and Fracture Risk in Diabetes Mellitus.

Puspitasari M, Purnamasari D, Setyohadi B, Isbagio H J ASEAN Fed Endocr Soc. 2021; 32(2):90-99.

PMID: 33442091 PMC: 7784240. DOI: 10.15605/jafes.032.02.14.

References

Mirza F, Padhi I, Raisz L, Lorenzo J . Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab. 2010; 95(4):1991-7. PMC: 2853994. DOI: 10.1210/jc.2009-2283. View

Modder U, Hoey K, Amin S, McCready L, Achenbach S, Riggs B . Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2010; 26(2):373-9. PMC: 3179347. DOI: 10.1002/jbmr.217. View

Modder U, Clowes J, Hoey K, Peterson J, McCready L, Oursler M . Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res. 2010; 26(1):27-34. PMC: 3132405. DOI: 10.1002/jbmr.128. View

Levey A, Coresh J, Greene T, Stevens L, Zhang Y, Hendriksen S . Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006; 145(4):247-54. DOI: 10.7326/0003-4819-145-4-200608150-00004. View

Ardawi M, Al-Kadi H, Rouzi A, Qari M . Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res. 2011; 26(12):2812-22. DOI: 10.1002/jbmr.479. View

Padhi D, Jang G, Stouch B, Fang L, Posvar E . Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2010; 26(1):19-26. DOI: 10.1002/jbmr.173. View

Rachner T, Khosla S, Hofbauer L . Osteoporosis: now and the future. Lancet. 2011; 377(9773):1276-87. PMC: 3555696. DOI: 10.1016/S0140-6736(10)62349-5. View

Amrein K, Amrein S, Drexler C, Dimai H, Dobnig H, Pfeifer K . Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab. 2011; 97(1):148-54. DOI: 10.1210/jc.2011-2152. View

Baron R, Rawadi G . Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007; 148(6):2635-43. DOI: 10.1210/en.2007-0270. View

10.

Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico R . Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab. 2010; 95(5):2248-53. DOI: 10.1210/jc.2010-0067. View

11.

Kirmani S, Amin S, McCready L, Atkinson E, Melton 3rd L, Muller R . Sclerostin levels during growth in children. Osteoporos Int. 2011; 23(3):1123-30. PMC: 3606589. DOI: 10.1007/s00198-011-1669-z. View

12.

Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M . Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10(5):537-43. DOI: 10.1093/hmg/10.5.537. View

13.

Krishnan V, Bryant H, MacDougald O . Regulation of bone mass by Wnt signaling. J Clin Invest. 2006; 116(5):1202-9. PMC: 1451219. DOI: 10.1172/JCI28551. View

14.

Polyzos S, Anastasilakis A, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E . Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide. Osteoporos Int. 2011; 23(3):1171-6. DOI: 10.1007/s00198-010-1525-6. View

15.

Cejka D, Jager-Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider D . Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant. 2011; 27(1):226-30. DOI: 10.1093/ndt/gfr270. View

16.

Bhattoa H, Nagy E, More C, Kappelmayer J, Balogh A, Kalina E . Prevalence and seasonal variation of hypovitaminosis D and its relationship to bone metabolism in healthy Hungarian men over 50 years of age: the HunMen Study. Osteoporos Int. 2012; 24(1):179-86. DOI: 10.1007/s00198-012-1920-2. View

17.

Randers E, Erlandsen E . Serum cystatin C as an endogenous marker of the renal function--a review. Clin Chem Lab Med. 1999; 37(4):389-95. DOI: 10.1515/CCLM.1999.064. View

18.

Sheng Z, Tong D, Ou Y, Zhang H, Zhang Z, Li S . Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women. Clin Endocrinol (Oxf). 2011; 76(6):797-801. DOI: 10.1111/j.1365-2265.2011.04315.x. View

19.

Drake M, Srinivasan B, Modder U, Peterson J, McCready L, Riggs B . Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab. 2010; 95(11):5056-62. PMC: 2968729. DOI: 10.1210/jc.2010-0720. View

20.

Kanis J, Melton 3rd L, Christiansen C, JOHNSTON C, Khaltaev N . The diagnosis of osteoporosis. J Bone Miner Res. 1994; 9(8):1137-41. DOI: 10.1002/jbmr.5650090802. View